Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer

Zupančič, Eva; Curato, Caterina; Kim, Jung Seok; Yeini, Eilam; Porat, Ziv; Viana, Ana S.; Levin, Anat Globerson; Waks, Tova; Eshhar, Zelig; Moreira, João Nuno; Satchi‐Fainaro, Ronit; Eisenbach, Lea; Florindo, Helena F.

doi:10.1016/j.nano.2017.12.011

Cited by 19 publications

(15 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering that most pathogens need to stimulate multiple TLRs to upregulate pro‐inflammatory cytokines and chemokines, nanovectors are engineered to combine a few TLR agonists. For example, poly( d , l ‐lactic‐ co ‐glycolic acid) (PLGA)/polyethylenimine (PEI) polymeric nanoparticles codeliver R848 (TLR7/8 agonist), MPLA (TLR4 agonist), and CpG (TLR9 agonist) with OVA, exerting superior effects on promoting robust immune responses in comparison to a single bioadjuvant, which is consistent with other studies …”

Section: Nanomaterials For Traditional and Novel Vaccine Deliverysupporting

confidence: 88%

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Liu

Zhang

2019

Small

116

View full text Add to dashboard Cite

Cancer immunotherapy is a promising cancer terminator by directing the patient's own immune system in the fight against this challenging disorder. Despite the monumental therapeutic potential of several immunotherapy strategies in clinical applications, the efficacious responses of a wide range of immunotherapeutic agents are limited in virtue of their inadequate accumulation in the tumor tissue and fatal side effects. In the last decades, increasing evidences disclose that nanotechnology acts as an appealing solution to address these technical barriers via conferring rational physicochemical properties to nanomaterials. In this Review, an imperative emphasis will be drawn from the current understanding of the effect of a nanosystem's structure characteristics (e.g., size, shape, surface charge, elasticity) and its chemical modification on its transport and biodistribution behavior. Subsequently, rapid‐moving advances of nanoparticle‐based cancer immunotherapies are summarized from traditional vaccine strategies to recent novel approaches, including delivery of immunotherapeutics (such as whole cancer cell vaccines, immune checkpoint blockade, and immunogenic cell death) and engineered immune cells, to regulate tumor microenvironment and activate cellular immunity. The future prospects may involve in the rational combination of a few immunotherapies for more efficient cancer inhibition and elimination.

show abstract

Section: Nanomaterials For Traditional and Novel Vaccine Deliverysupporting

confidence: 88%

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Liu

Zhang

2019

Small

116

View full text Add to dashboard Cite

show abstract

“…Here we designed an experimental system to identify transcriptomic changes in LN DC, which resulted from cognate T cell encounter. A nanoparticulate system harboring a label, antigen (OVA), and adjuvant (CpG) (29, 39) was used to induce antigen-specific T H 1 response in OVA-responding TCR transgenic CD4 + cells (OT-II). NP were efficiently ingested by MHC II-expressing cells and induced robust antigen-specific T cell responses with minimal bystander activation.…”

Section: Discussionmentioning

confidence: 99%

DC Respond to Cognate T Cell Interaction in the Antigen-Challenged Lymph Node

et al. 2019

Self Cite

View full text Add to dashboard Cite

Dendritic cells (DC) are unrivaled in their potential to prime naive T cells by presenting antigen and providing costimulation. DC are furthermore believed to decode antigen context by virtue of pattern recognition receptors and to polarize T cells through cytokine secretion toward distinct effector functions. Diverse polarized T helper (T H ) cells have been explored in great detail. In contrast, studies of instructing DC have to date largely been restricted to in vitro settings or adoptively transferred DC. Here we report efforts to unravel the DC response to cognate T cell encounter in antigen-challenged lymph nodes (LN). Mice engrafted with antigen-specific T cells were immunized with nanoparticles (NP) entrapping adjuvants and absorbed with antigen to study the immediate DC response to T cell encounter using bulk and single cell RNA-seq profiling. NP induced robust antigen-specific T H 1 cell responses with minimal bystander activation. Fluorescent-labeled NP allowed identification of antigen-carrying DC and focus on transcriptional changes in DC that encounter T cells. Our results support the existence of a bi-directional crosstalk between DC and T cells that promotes T H 1 responses, including involvement of the ubiquitin-like molecule Isg15 that merits further study.

show abstract

“…Subunit vaccines have also been developed for use as cancer vaccines (227), which are being tested with many of the same delivery systems as nucleic acid-based cancer vaccines to maximize vaccine targeting to immune cells (228). NP-based vaccines in particular have been developed and tested for use as cancer treatments (228)(229)(230)(231)(232)(233)(234)(235), the most notable of which are several HPV vaccines for prevention of cervical cancer (236). While less development has been done on VLP-based cancer vaccines, one notable target that has been used is the widely expressed cancer antigen human epidermal growth factor receptor-2/neu (HER2), which has shown to be immunogenic in mouse models (237)(238)(239)(240)(241)(242)(243)(244) and in early clinical testing in humans (245) and dogs (246), but as a whole these vaccines have had to undergo additional design in order to overcome B cell tolerance (227,247) and to fully characterize their antitumor activity.…”

Section: Therapeutic Vaccines For Noncommunicable Diseasesmentioning

confidence: 99%

Emerging Concepts and Technologies in Vaccine Development

et al. 2020

View full text Add to dashboard Cite

Despite the success of vaccination to greatly mitigate or eliminate threat of diseases caused by pathogens, there are still known diseases and emerging pathogens for which the development of successful vaccines against them is inherently difficult. In addition, vaccine development for people with compromised immunity and other pre-existing medical conditions has remained a major challenge. Besides the traditional inactivated or live attenuated, virus-vectored and subunit vaccines, emerging non-viral vaccine technologies, such as viral-like particle and nanoparticle vaccines, DNA/RNA vaccines, and rational vaccine design, offer innovative approaches to address existing challenges of vaccine development. They have also significantly advanced our understanding of vaccine immunology and can guide future vaccine development for many diseases, including rapidly emerging infectious diseases, such as COVID-19, and diseases that have not traditionally been addressed by vaccination, such as cancers and substance abuse. This review provides an integrative discussion of new non-viral vaccine development technologies and their use to address the most fundamental and ongoing challenges of vaccine development.

show abstract

Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer

Cited by 19 publications

References 39 publications

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

DC Respond to Cognate T Cell Interaction in the Antigen-Challenged Lymph Node

Emerging Concepts and Technologies in Vaccine Development

Contact Info

Product

Resources

About